New drugs treat leukemia rarely in humans

On September 4, the US Food and Drug Administration (FDA) approved a new drug to treat rare leukemia in humans.

>>>Korea modulates new drugs to treat leukemia

Bosulif drugs will inhibit the enzyme that develops white blood cells

The drug, called Bosulif , produced by Pfizer Inc, is used to treat chronic myelogenous leukemia (CML), a blood and bone marrow cancer that often affects older people.

Most people with CML often have mutations in the Philadelphia chromosome, making the bone marrow produce an enzyme that causes the abnormal development of white blood cells.

Bosulif drugs will help prevent enzymes from producing white cells. Not only that, but it can also replace drugs such as Gleevec Novartis AG or previous cancer treatments for people with CML.

According to FDA estimates, currently in the United States, there are about 26,000 people living with cancer, and 5,430 people with CML cancer each year.